ARCHIVES

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

This article is from The Cancer Letter archive.

Vol. 30 No. 41 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

Postdoc Fabricated Results In Published Study, ORI Says.

October 27, 2000

DCCP Board Okays Concepts Of New Grants Totaling $1.4 Million Year

February 18, 1983

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

January 31, 2014

Celecoxib Effective To Prevent Colon Adenomas, Study Finds

April 25, 2008

In Brief: NCAB To Meet Jan. 15-17; UCLA To Compete For Clinical Neutron Therapy Contract

January 5, 1979

NCAB Rejects Automatic Loss Of Comprehensive Status For Center Without Core Grants

September 29, 1978